Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of high-dose nusinersen in participants with 5q spinal muscular atrophy previously enrolled in a nusinersen investigational study
CTR20232342Phase 3Active
- Sponsor
- Biogen
- Start
- Nov 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Started Nov 2023; status: active.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on CTR20232342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232342.